A clinical trial showed that pioglitazone, apart from enhancing insulin sensitivity, also improved steatosis, inflammation, hepatocellular damage, and liver-enzyme levels of non-alcoholic steatohepatic patients [63]. The gene discussed is INS; the disease is steatosis.